Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.25 USD
+0.04 (0.49%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $8.24 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Theravance Biopharma (TBPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.75 | $21.00 | $9.00 | 66.67% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Theravance Biopharma comes to $13.75. The forecasts range from a low of $9.00 to a high of $21.00. The average price target represents an increase of 66.67% from the last closing price of $8.25.
Analyst Price Targets (4 )
Broker Rating
Theravance Biopharma currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, two are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 60%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TBPH.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.20 | 2.20 | 1.80 | 1.80 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/6/2024 | SVB Securities | David Risinger | Strong Buy | Hold |
8/6/2024 | Evercore Partners | Liisa A Bayko | Hold | Hold |
8/6/2024 | Cowen & Co. | Marc Frahm | Hold | Hold |
5/14/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
4/12/2024 | BTIG | Julian Harrison | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 5 |
Average Target Price | $13.75 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 94 of 253 |
Current Quarter EPS Est: | -0.10 |